At the Uro-oncology Centre for Prostate and Kidney, various medical specialist groups work closely together to jointly determine an optimal treatment plan for each patient.
Our joint work is based on the current scientific recommendations of the national and international specialist associations (so-called S3 guidelines). In weekly interdisciplinary tumour conferences, individual treatment recommendations are developed for patients with kidney cancer and prostate cancer. Patients also have the opportunity to obtain advice on treatment options for prostate cancer in an interdisciplinary consultation (urologist and radiotherapist). Our services are complemented by the psycho-oncology, social services and palliative medicine departments.
Functional results after robotic radical prostatectomy
Continence and potency are issues that make a decisive contribution to the quality of life of prostate cancer patients. As part of the Prostate Cancer Outcomes (PCO) study, in which the Claraspital is also involved, the German Cancer Society has carried out a quality of outcome comparison of the participating prostate cancer centres. The data was collected using anonymised patient questionnaires (one week before the operation and one year after the operation).
Quality label
The Uro-oncology Centre is certified by the German Cancer Society (DKG). The German Cancer Society (DKG) is a worldwide neutral quality mark for good oncological care. The DKG certifies that patients benefit from treatment in accordance with the highest international quality guidelines, which can support them in their choice of hospital and create the necessary trust. Patients in certified cancer centres have a significantly lower risk of death. DKG-certified cancer centres are subject to annual quality control, must implement the latest scientific findings and use state-of-the-art technology.
Certifications
Uro-oncology centre
Certifications
Recognised A2 training centre
Contact information
How you can reach us
Tumour board
An interdisciplinary tumour conference is held six times a week. All specialists - radiologists, pathologists, surgeons, medical oncologists and radiotherapists - are present at these meetings. The radiologists demonstrate the relevant X-ray findings, the pathologists comment on the tissue examinations and the surgeons, medical oncologists and radiation oncologists jointly discuss the treatment strategy, which in many cases includes surgical, radiotherapeutic and chemotherapeutic intervention.
General practitioners and attending physicians can also take part in the tumour board and contribute further aspects, including those relating to the patient's family situation and social environment. The clinical picture of each individual patient is discussed together and the therapy plan for the treatment is determined as a team. Registration is requested